Loading...
NPI 1962956201 · Torrance, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Chabado Genomics Inc is a clinical medical laboratory provider located in Torrance, California. This profile covers 11 Medicare and 31 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Chabado Genomics Inc |
| Address | 3870 Del Amo Blvd |
| City | Torrance |
| State | CA |
| ZIP | 90503 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 3, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.6M |
| Medicaid | $324.7K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,410 | $240 | $2M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 11,290 | $60 | $688.9K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 9,430 | $30 | $320.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 830 | $200 | $161.7K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,030 | $140 | $144.2K |
| 82043 | The lab analyst quantitates a timed or random urine specimen for the measurement of albumin. Random means the specimen collection may occur without respect to the time of day. This is a valuable… | 11,420 | $10 | $68.5K |
| 84133 | The lab analyst performs a test to evaluate the level of potassium in a patient urine specimen. | 11,530 | $10 | $57.6K |
| 84300 | The lab analyst performs a test to measure the concentration of sodium in urine, in either a random specimen or a specimen collected over 24 hours. | 11,530 | $10 | $57.6K |
| 82436 | The lab analyst measures the amount of chloride in the urine specimen. Chloride is an important ion needed for electrolyte balance. | 6,400 | $10 | $38.4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 320 | $30 | $10.9K |
Showing 1–10 of 11
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
31 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,180 | $20 | $119.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,060 | $30 | $55.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,170 | $20 | $32.6K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 340 | $50 | $16.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 480 | $30 | $13.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 1,850 | $1 | $7.4K |
| 82043 | The lab analyst quantitates a timed or random urine specimen for the measurement of albumin. Random means the specimen collection may occur without respect to the time of day. This is a valuable… | 3,400 | $1 | $6.8K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 220 | $30 | $6.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 170 | $30 | $5.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 180 | $30 | $5.3K |
Showing 1–10 of 31
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
31 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 45 | 60 | 370 | $80 | $4.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 23 | 100 | 520 | $120 | $2.4M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 520 | 750 | 950 | $50 | $890K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 282 | 660 | 1,490 | $30 | $417.2K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 61 | 290 | 220 | $210 | $268.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 400 | 520 | 470 | $10 | $116K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 28 | 50 | 180 | $180 | $85K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 276 | 470 | 350 | $40 | $76.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 87 | 400 | 330 | $20 | $67.9K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 68 | 150 | 180 | $40 | $65.2K |
Showing 1–10 of 31
Other providers in the same ZIP code as Chabado Genomics Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Providence Health System Southern California | CA | General Acute Care Hospital | $0 | $27.2M |
| Mehran Taban M.d. Inc. | CA | Ophthalmology Physician | $0 | $24.1M |
| Vitae Diagnostics Incorporated | CA | Clinical Medical Laboratory | $608.6K | $5.1M |
| Mehran Taban | CA | Ophthalmology Physician | $3.2M | $81.3K |
| Michael Heeg | CA | Ophthalmology Physician | $2.6M | $0 |
| Ron Gallemore | CA | Ophthalmology Physician | $2.3M | $7K |
| Little Company Of Mary Ancillary Services Corporation | CA | Radiology Clinic/Center | $1M | $356.8K |
| Babak Shabatian | CA | Ophthalmology Physician | $1.2M | $0 |
| Kenneth Bradley | CA | Pain Medicine Physician | $1.2M | $4.2K |
| John Kennedy | CA | Cardiovascular Disease Physician | $596K | $548.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.